Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 46

1.

[Prophylaxis of cytomegalovirus infection in intestinal transplantation].

Martín-Dávila P, Fortún-Abete J, San Juan R.

Enferm Infecc Microbiol Clin. 2011 Dec;29 Suppl 6:60-4. doi: 10.1016/S0213-005X(11)70061-1. Spanish.

PMID:
22541926
2.

[Effectiveness of preemptive therapy with ganciclovir in recipients of renal transplants at high risk (R-/D+) for the development of cytomegalovirus disease].

Aranda-Verástegui F, Alberú J, Soto-Ramírez LE, González-Aguirre H, Muñoz Trejo T, Mancilla E, Díliz H, Correa-Rotter R, Sierra-Madero J.

Rev Invest Clin. 2002 May-Jun;54(3):198-203. Spanish.

PMID:
12183888
3.

[Prophylaxis of cytomegalovirus infection in renal transplantation].

Aguado JM, Gil Vernet S.

Enferm Infecc Microbiol Clin. 2011 Dec;29 Suppl 6:38-41. doi: 10.1016/S0213-005X(11)70056-8. Review. Spanish.

PMID:
22541921
4.

[Prophylaxis of cytomegalovirus infection in heart transplantation].

Muñoz P, Crespo Leiro MG.

Enferm Infecc Microbiol Clin. 2011 Dec;29 Suppl 6:52-5. doi: 10.1016/S0213-005X(11)70059-3. Spanish.

PMID:
22541924
5.

Prevention and treatment of cytomegalovirus infection in organ transplant recipients.

Kusne S, Shapiro R, Fung J.

Transpl Infect Dis. 1999 Sep;1(3):187-203. Review.

PMID:
11428989
6.

[Prophylaxis of cytomegalovirus infection in pancreatic transplantation].

Moreno Camacho A, Rodríguez Benot A.

Enferm Infecc Microbiol Clin. 2011 Dec;29 Suppl 6:56-9. doi: 10.1016/S0213-005X(11)70060-X. Spanish.

PMID:
22541925
7.

[Prophylaxis of cytomegalovirus infection in liver transplantation].

Cisneros JM, Varo E.

Enferm Infecc Microbiol Clin. 2011 Dec;29 Suppl 6:42-5. doi: 10.1016/S0213-005X(11)70057-X. Spanish.

PMID:
22541922
8.

A randomized prospective trial of oral versus intravenous ganciclovir for prophylaxis of cytomegalovirus infection and disease in high-risk kidney recipients.

Nafar M, Pezeshki ML, Farrokhi F, Einollahi B, Pour-Reza-Gholi F, Firouzan A, Farhangi S.

Transplant Proc. 2005 Sep;37(7):3053-5.

PMID:
16213302
11.

Acyclovir plus CMV immunoglobulin prophylaxis and early therapy with ganciclovir are effective and safe in CMV high-risk renal transplant pediatric recipients.

Ginevri F, Losurdo G, Fontana I, Rabagliati AM, Bonatto L, Valente R, Venzano P, Nocera A, Basile GC, Valente U, Gusmano R.

Transpl Int. 1998;11 Suppl 1:S130-4.

12.

Prospective comparison of valacyclovir and oral ganciclovir for prevention of cytomegalovirus disease in high-risk renal transplant recipients.

Reischig T, Opatrný Jr K, Treska V, Mares J, Jindra P, Svecová M.

Kidney Blood Press Res. 2005;28(4):218-25. Epub 2005 Jul 21.

13.

Long-term oral ganciclovir prophylaxis for prevention of cytomegalovirus infection and disease in cytomegalovirus high-risk renal transplant recipients.

Kletzmayr J, Kreuzwieser E, Watkins-Riedel T, Berlakovich G, Kovarik J, Klauser R.

Transplantation. 2000 Oct 27;70(8):1174-80.

PMID:
11063336
14.

Prevention of primary cytomegalovirus disease in organ transplant recipients with oral ganciclovir or oral acyclovir prophylaxis.

Rubin RH, Kemmerly SA, Conti D, Doran M, Murray BM, Neylan JF, Pappas C, Pitts D, Avery R, Pavlakis M, Del Busto R, DeNofrio D, Blumberg EA, Schoenfeld DA, Donohue T, Fisher SA, Fishman JA.

Transpl Infect Dis. 2000 Sep;2(3):112-7.

PMID:
11429021
15.

Cytomegalovirus prophylaxis with ganciclovir in kidney transplant recipients receiving induction antilymphocyte antibodies.

Said T, Nampoory MR, Johny KV, Pacsa AS, Mini Abraham P, Nair MP, Abdel-Haleem M, Samhan M, Al-Mousawi M.

Transplant Proc. 2004 Jul-Aug;36(6):1847-9.

PMID:
15350495
16.

A prospective randomized study of acyclovir versus ganciclovir plus human immune globulin prophylaxis of cytomegalovirus infection after solid organ transplantation.

Dunn DL, Gillingham KJ, Kramer MA, Schmidt WJ, Erice A, Balfour HH Jr, Gores PF, Gruessner RW, Matas AJ, Payne WD, et al.

Transplantation. 1994 Mar 27;57(6):876-84.

PMID:
8154035
17.

A randomized prospective controlled trial of oral acyclovir versus oral ganciclovir for cytomegalovirus prophylaxis in high-risk kidney transplant recipients.

Flechner SM, Avery RK, Fisher R, Mastroianni BA, Papajcik DA, O'Malley KJ, Goormastic M, Goldfarb DA, Modlin CS, Novick AC.

Transplantation. 1998 Dec 27;66(12):1682-8.

PMID:
9884259
18.

A comparative randomised study of valacyclovir vs. oral ganciclovir for cytomegalovirus prophylaxis in renal transplant recipients.

Pavlopoulou ID, Syriopoulou VP, Chelioti H, Daikos GL, Stamatiades D, Kostakis A, Boletis JN.

Clin Microbiol Infect. 2005 Sep;11(9):736-43.

19.

[The significance of risk-adapted antiviral prophylaxis and modern virus diagnosis for organ survival after kidney transplantation].

Fricke L, Steinhoff J, Hartwig-Weber I, Bein G.

Dtsch Med Wochenschr. 1997 May 2;122(18):565-71. German.

PMID:
9190308
20.

The incidence of cytomegalovirus infection in lung transplant recipients under universal prophylaxis with intravenous ganciclovir.

Schröeder R, Michelon T, Wurdig J, Fagundes I, Schio S, Sanchez L, Camargo JJ, Sukkienik TC, Pasqualotto AC, Neumann J.

Braz J Infect Dis. 2007 Apr;11(2):212-4.

Supplemental Content

Support Center